Insider Buying: Cocrystal Pharma (NASDAQ:COCP) Director Purchases 20,000 Shares of Stock

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost acquired 20,000 shares of the firm’s stock in a transaction on Tuesday, December 30th. The stock was purchased at an average price of $0.97 per share, with a total value of $19,400.00. Following the purchase, the director owned 1,788,551 shares in the company, valued at approximately $1,734,894.47. The trade was a 1.13% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, December 26th, Phillip Md Et Al Frost bought 40,000 shares of Cocrystal Pharma stock. The stock was acquired at an average price of $0.97 per share, for a total transaction of $38,800.00.
• On Wednesday, December 24th, Phillip Md Et Al Frost bought 25,000 shares of Cocrystal Pharma stock. The stock was acquired at an average cost of $0.97 per share, with a total value of $24,250.00.
• On Wednesday, November 26th, Phillip Md Et Al Frost purchased 4,000 shares of Cocrystal Pharma stock. The shares were acquired at an average price of $0.99 per share, for a total transaction of $3,960.00.
• On Tuesday, November 25th, Phillip Md Et Al Frost acquired 20,000 shares of Cocrystal Pharma stock. The stock was acquired at an average cost of $0.94 per share, for a total transaction of $18,800.00.

Cocrystal Pharma Stock Performance

NASDAQ:COCP traded up $0.03 during trading on Wednesday, reaching $0.98. The company’s stock had a trading volume of 138,674 shares, compared to its average volume of 424,764. Cocrystal Pharma, Inc. has a 12 month low of $0.90 and a 12 month high of $2.67. The firm has a market cap of $13.49 million, a price-to-earnings ratio of -1.04 and a beta of 1.05. The firm has a 50 day moving average of $1.03 and a 200-day moving average of $1.32.

Cocrystal Pharma (NASDAQ:COCP) last released its earnings results on Friday, November 14th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03. Equities research analysts forecast that Cocrystal Pharma, Inc. will post -1.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Cocrystal Pharma presently has an average rating of “Hold” and a consensus price target of $6.00.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.